The purpose of this trial is to find out how safe and effective it is to have either one or two immunotherapy drugs alongside the parp inhibitor Rucaparib. Researchers want to find out if using the different combination of drugs will prolong the time it takes for your cancer to come back compared with being treated with Rucaparib on its own. The…

The purpose of this study is to help researchers better understand how niraparib is used in the UK and how well it's tolerated by those taking it.Niraparib is a type of drug known as a PARP inhibitor. PARP inhibitors are a relatively new class of drugs known as targeted therapies. In this study the researchers wish to collect real time information …

This study is looking at using a drug called TAK228 (new drug) in combination with paclitaxel (a standard chemotherapy drug) to see if it's a more effective way of treating ovarian cancer. The drugs involved in this trial are: TAK228 (new drug) – a drug that is thought to interfere with cell growth and may slow or stop cancer cells from di…

In this trial, the researchers are trying to find out whether it's safe and effective to use a PARP inhibitor rather than standard chemotherapy in women with a BRCA gene mutation who've had two previous chemotherapy treatments. The drugs involved in this trial: Rucaparib – a targeted treatment known as a PARP inhibitor Paclitaxel – a sta…